JAK1 and Increased total eosinophil count: The two patients reported by Del Bel et al. were treated with ruxolitinib (a JAK1/2 inhibitor), and they demonstrated improvements in pruritus, appetite loss, sleep disturbance and eosinophilia, and achieved weight gain, as well as resolution of skin lesions and hepatosplenomegaly (6).